2011

1. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A phase 2, randomised, double-blind, placebo-controlled study

   The Lancet Oncology, Vol. 12, Núm. 4, pp. 369-376